Kang Le Pharmaceutical Company

"Kangle Medicine Welcomes You"!
Our company promises: Honesty, genuine products at reasonable prices, selling conscientious medicines, cash on delivery,
Beijing Kangle Medicine
Contact person: Manager Bai (Ms.)
Contact number QQ
India Gleevec imatinib/box
Gleevec price for sale Gleevec, India Gleevec, Gleevec price Gleevec? For example of prescription information, please look at the following for details from Europe Product summary.
Please note that this information may differ from the regulations in your country. For detailed information, please contact your local Novartis representative. The product packaging of Gleevec® is mg/capsule, medical product name (Gleevec®) mg/hard capsule, Liu Hui, Department of Hematology, Beijing Hospital of the Ministry of Health, product properties and ingredients. Each capsule contains mg of A Imatinib Sulfonate For excipients, see. , Drug Specifications
Hard Capsules White and yellow drug powder packed into an orange or light gray opaque capsule marked with the logo. , clinical characteristics, treatment indications, Gleevec is suitable for the treatment of Philadelphia chromosome (Brb) positive, chronic leukemia (chronic phase, chronic phase in which h interferon treatment has failed, or in blast phase or accelerated phase) ( M). The effectiveness of Gleevec® is demonstrated in terms of complete hematological and cytogenetic response rates, and there are no controlled trials demonstrating clinical benefit or survival prolongation. Administration and dosage are recommended by a physician experienced in treating patients with M. Prescription should be taken orally once a day with a meal and plenty of water.
The recommended dose for patients with chronic phase chronic myelogenous leukemia is mg/day. Chronic phase chronic myelogenous leukemia is defined as having all of the following criteria: % blasts in the blood and bone marrow. Percentage of basophils in peripheral blood and platelet count. The recommended dosage of Gleevec® for treatment of M patients in accelerated phase is mg/day. The accelerated phase refers to the presence of any of the following criteria: the proportion of blast cells in the blood and bone marrow
% but the proportion of blast cells plus promyelocytes % (blast cells %) basophils in peripheral blood Cell ratio %, platelet count/, but not related to treatment. The recommended dose of Gleevec® for the treatment of M patients in blast crisis is mg/day. M in the blast phase refers to the proportion of primitive cells in the blood and bone marrow, or the occurrence of external lesions other than liver and spleen enlargement. Duration of treatment: Clinical studies have shown that treatment with Gleevec can be continued until disease progression. The impact of discontinuation of treatment on patients who achieve complete cytogenetic remission has not been studied. When treating M patients in the chronic phase, the dose of Gleevec can be increased from mg to mg, and when treating M patients in the accelerated phase or blast phase, the dose can be increased from mg to mg, but first it must be taken into account that no serious disease has occurred. Adverse drug reactions and severe non-leukemia-related neutrophils or thrombocytopenia, and the following treatment conditions occur
Disease progression (occurring at any time) without obtaining a satisfactory hematology after at least months of treatment Loss of previously achieved hematological response. Taking into account the increased potential for adverse reactions after increasing the dose, patients must increase their dosage under close monitoring. Non-hematological adverse reactions If serious non-hematological adverse reactions occur during treatment with Gleevec®, treatment should be interrupted until the event resolves. Therefore
The appropriate dosage for restarting treatment should be based on the severity of the initial event. If the patient's bilirubin level increases by more than U times the upper limit of the normal range or the liver aminotransferase level increases by more than U times during treatment, Gleevec® should be discontinued until the patient's bilirubin level increases by more than U times. If the level drops below . times of U or the transaminase level drops below . times of U, and then Gleevec® is used to continue treatment, the daily dose of the drug should be reduced (for example, mg
is reduced to mg per day or to mg to mg). Hematological adverse reactions It is recommended to reduce dosage if severe neutropenia and thrombocytopenia as mentioned in the table below occur during treatment with Gleevec®
dosage or discontinuation.